G Cartron

Summary

Country: France

Publications

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
  2. ncbi Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
    G Cartron
    EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, Universite Francois Rabelais, Tours
    Ann Oncol 19:1485-7. 2008
  3. ncbi [Immunologic effects of anti-B-lymphocyte antibodies]
    G Cartron
    , clinique Victor-Hugo, Le Mans, France
    Rev Med Interne 26:42-6. 2005
  4. ncbi Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma
    G Cartron
    Department of Hematology of Tours, France
    Leuk Lymphoma 40:529-40. 2001
  5. ncbi Maintenance therapy for low-grade lymphomas: has the time come?
    Guillaume Cartron
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU de Montpellier, France
    Curr Opin Oncol 19:425-32. 2007
  6. ncbi Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Guillaume Cartron
    Universite Francois Rabelais, UPRES EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques IPGA, Tours, France
    Crit Rev Oncol Hematol 62:43-52. 2007
  7. ncbi Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand
    G Cartron
    Laboratory of Hematology, CHRU Bretonneau, Tours, France
    Int J Hematol 77:133-41. 2003
  8. ncbi A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels
    L Benboubker
    Department of Hematology Oncology, H pital Bretonneau, Tours, France
    Ann Oncol 11:1485-91. 2000
  9. ncbi From the bench to the bedside: ways to improve rituximab efficacy
    Guillaume Cartron
    UPRES EA Immuno Pharmaco Génétique des Anticorps thérapeutiques, UPRES EA, Universite Francois Rabelais, Tours, France
    Blood 104:2635-42. 2004
  10. ncbi Evaluation of a peptide ELISA for the detection of rituximab in serum
    H Blasco
    Université François Rabelais Tours, EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, IFR 135, F 37032 Tours, France
    J Immunol Methods 325:127-39. 2007

Collaborators

  • Gilles Paintaud
  • L Benboubker
  • Herve Watier
  • Ph Solal-Céligny
  • Ph Colombat
  • O Herault
  • N Milpied
  • Josee Golay
  • T Girinsky
  • Pascal Girard
  • Marion Baudard
  • David Ternant
  • Marc Ohresser
  • David Daydé
  • Gérard Ganem
  • H Blasco
  • Severine Loisel
  • Pierre Bardos
  • Christian Berthou
  • Florence Dommange
  • Elena Cittera
  • Marc Bernard
  • Sophie Tartas
  • J Domenech
  • Jean Marc Cosset
  • Rick L M Haas
  • Alain Le Pape
  • Emilie Hénin
  • Stephanie Lerondel
  • Michel Tod
  • Sabrina Pesnel
  • M C Maurel
  • E Chatelut
  • S Canepa
  • G Lalmanach
  • M Belghazi
  • C Le Guellec
  • E Godat
  • D Degenne
  • Marc Pallardy
  • Nathalie Gallay
  • Claire Espanel
  • Chistian Binet
  • Jorge Domenech
  • Andrea Biondi
  • Giovanni Cazzaniga
  • Annick LeMevel
  • Vincent Delwail
  • Philippe Cassasus
  • Bernard Desablens
  • Christiane Ghandour
  • Catherine Le Maignan
  • Philippe Solal Celigny
  • Bernard Branger
  • Leopoldo Zelante
  • Martino Introna
  • Chiara Onofri
  • Petronella Rachieru
  • Thierry Lamy
  • Paolo Paolucci
  • Dominique Guyotat
  • Gilles Thibault
  • I Desbois
  • D Truglio
  • F Roingeard
  • C Binet
  • N Clement
  • M-H Estienne

Detail Information

Publications24

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  2. ncbi Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
    G Cartron
    EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, Universite Francois Rabelais, Tours
    Ann Oncol 19:1485-7. 2008
    ..We formulated the hypothesis that if neutrophils are critical cells for in vivo rituximab activity, FcgammaRIIIb-NA1/NA2 polymorphism could influence the response to rituximab...
  3. ncbi [Immunologic effects of anti-B-lymphocyte antibodies]
    G Cartron
    , clinique Victor-Hugo, Le Mans, France
    Rev Med Interne 26:42-6. 2005
  4. ncbi Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma
    G Cartron
    Department of Hematology of Tours, France
    Leuk Lymphoma 40:529-40. 2001
    ....
  5. ncbi Maintenance therapy for low-grade lymphomas: has the time come?
    Guillaume Cartron
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU de Montpellier, France
    Curr Opin Oncol 19:425-32. 2007
    ..The introduction of rituximab (MabThera, Rituxan) maintenance treatment has initiated a new era in the management of low-grade non-Hodgkin's lymphomas...
  6. ncbi Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Guillaume Cartron
    Universite Francois Rabelais, UPRES EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques IPGA, Tours, France
    Crit Rev Oncol Hematol 62:43-52. 2007
    ..This review focuses on the current knowledge on rituximab pharmacokinetics and on factors influencing individual exposure and suggests ways to improve its clinical use...
  7. ncbi Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand
    G Cartron
    Laboratory of Hematology, CHRU Bretonneau, Tours, France
    Int J Hematol 77:133-41. 2003
    ..However, the stimulatory effects of these GF used alone were dependent on the presence of a stromal layer. CONCLUSION: These LTMC data emphasize the particular roles for FL and MGDF in the stimulation of primitive hematopoiesis...
  8. ncbi A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels
    L Benboubker
    Department of Hematology Oncology, H pital Bretonneau, Tours, France
    Ann Oncol 11:1485-91. 2000
    ..This report aims to investigate the prognostic value of a new serologic index combining sCA125 and LDH serum levels...
  9. ncbi From the bench to the bedside: ways to improve rituximab efficacy
    Guillaume Cartron
    UPRES EA Immuno Pharmaco Génétique des Anticorps thérapeutiques, UPRES EA, Universite Francois Rabelais, Tours, France
    Blood 104:2635-42. 2004
    ..A better understanding of how rituximab acts in vivo should make it possible to develop new and more effective therapeutic strategies...
  10. ncbi Evaluation of a peptide ELISA for the detection of rituximab in serum
    H Blasco
    Université François Rabelais Tours, EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, IFR 135, F 37032 Tours, France
    J Immunol Methods 325:127-39. 2007
    ..However, the discrepancy observed between two different approaches for rituximab measurement indicates that data from different studies should be interpreted with care...
  11. ncbi Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma
    David Ternant
    Université François Rabelais Tours, GICC, Tours, France
    Br J Clin Pharmacol 68:561-73. 2009
    ..The aim of this study was to develop a PK-PD model of rituximab in relapsed/resistant follicular NHL (FL)...
  12. ncbi Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé
    Genetique, Immunothérapie, Chimie et Cancer, Universite Francois Rabelais, Tours, France
    Blood 113:3765-72. 2009
    ..Furthermore, rituximab exposure influenced response and survival. Finally, using a pharmacokinetic-pharmacodynamic model, we demonstrated that tumor burden significantly influenced rituximab efficacy...
  13. ncbi Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?
    Ph Solal-Céligny
    Centre J Bernard, Service d Hematologie, Le Mans, France
    Int J Hematol 92:246-54. 2010
    ..Up to now, these biological study results are more useful for approaching the pathophysiology of FL rather than to be used as prognostic tools in clinical practice...
  14. ncbi Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation
    J Domenech
    UPRES-EA 3249, Laboratory of Hematology, University Hospital of Tours, Tours, France
    Bone Marrow Transplant 29:557-62. 2002
    ..These results indicate impaired proliferative potential of marrow CD34(+) cells several months after ABMT involving erythroid progenitor cells and/or commitment towards erythroid lineage from a more immature stage (pre-CFU)...
  15. ncbi Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship
    Sophie Tartas
    Laboratoire d'Immunologie, , Tours, France
    Cancer Res 64:4664-9. 2004
    ..Rituximab administration could therefore be adjusted according to FCGR3A genotype...
  16. ncbi Quantitative and qualitative analysis of the human primitive progenitor cell compartment after autologous stem cell transplantation
    Guillaume Cartron
    Laboratory of Hematology and Department of Medical Oncology and Blood Diseases, University Hospital, Tours, France
    J Hematother Stem Cell Res 11:359-68. 2002
    ..This study indicates that both quantitative and qualitative abnormalities of the primitive progenitor cell compartment are a constant feature up to 4 years after autologous stem cell transplantation...
  17. ncbi Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow
    Lotfi Benboubker
    Laboratory of Hematology, UPRES-EA 3249, Faculty of Medicine and University Hospital of Tours, Tours, France
    Exp Hematol 31:89-97. 2003
    ..G-CSF-mobilized PBPCT resulted in faster neutrophil recovery compared to GM-CSF mobilization, with no difference in long-term hematopoietic reconstitution...
  18. ncbi Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks
    Gérard Ganem
    Department of Radiation Oncology, Centre Jean Bernard, Le Mans, France
    Int J Radiat Oncol Biol Phys 78:975-82. 2010
    ..Follicular lymphoma is probably an ideal model to explore these mechanisms. This review also discusses the future of LDRT for follicular lymphoma...
  19. ncbi Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study
    Guillaume Cartron
    Centre hospitalier universitaire CHU, Service d Hématologie et d Oncologie Médicale, Montpellier, France
    J Clin Oncol 26:2725-31. 2008
    ..A phase II clinical study combining GM-CSF and rituximab was initiated in patients with relapsed follicular lymphoma (FL) to determine the clinical and biologic responses, as well as safety of the combination...
  20. ncbi Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies
    David Ternant
    Blood 106:1503-4; author reply 1504-5. 2005
  21. ncbi Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines
    Elena Cittera
    Laboratory of Molecular Immunohaematology, Department of Immunology, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy
    Cancer Immunol Immunother 54:273-86. 2005
    ..These data demonstrate that rituximab alone has direct signalling capacity in different B-lymphoma lines, inducing distinct but overlapping sets of genes which may play a role in the biological and/or therapeutic effect of the antibody...
  22. ncbi Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
    Severine Loisel
    Universite de Bretagne Occidentale, Laboratoire de Thérapie Cellulaire et d Immunobiologie du Cancer, EA 2216, 29609 Brest Cedex, France
    Crit Rev Oncol Hematol 62:34-42. 2007
    ..In doing so, this article aims to provide a critical review of the animal models used in preclinical studies of mAbs for cancer treatment. In particular, their relevance, advantages and limitations will be discussed...
  23. ncbi CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia
    Florence Dommange
    CHRU de Tours, Laboratoire d Hematologie, Service d Hématologie et Thérapie Cellulaire
    FASEB J 20:1913-5. 2006
    ....
  24. ncbi Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study
    Marc Bernard
    Haematologica 90:802-9. 2005
    ..INTERPRETATION AND CONCLUSIONS: High-dose CHOP followed by locoregional radiotherapy is a feasible treatment for localized high-grade NHL. It has very few complications, a good CR rate and the OS is 78% at 10 years...